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alternative marker or biomarker is needed to draw 
out the severity of skin fibrosis in more objective 
and rigorous way.2,5 Further, the mentioned marker/
biomarker should be highly correlated with the 
clinical manifestation used in mRSS scoring, so it 
can be used as an alternative test.6  
Development in the knowledge regarding 
the pathophysiology of systemic sclerosis has 
found that B-cell plays roles in excess fibroblast 
activation and collagen production.7-10 B-cell 
Activating Factor (BAFF) serves as a positive 
regulator of cell function by playing role in B-cell 
survival and maturation.8,11-13 Researches regarding 
the correlation between mRSS and serum BAFF 
levels have been done previously, though there is 
several controversies regarding the results of those 
researches.10,14,15 This study was expected to affirm 
the controversy that occurred in those previous 
studies by identifying the relationship between the 
degree of skin fibrosis based on mRSS and the level 




This is an analytic, descriptive research with a 
cross sectional design. Samples were collected 
consecutively at a specifiec time range. Subjects 
included in this study were all systemic sclerosis 
patients,  who fulfill the ACR EULAR 2013 for 
SSc, came to Rheumatology Clinic of Hasan 
Sadikin Hospital, Bandung November 2015 till 
March 2016. Samples were excluded if they 
were known having cell malignancy (malignant 
lymphoma, multiple myeloma), overlap syndrome, 
mix connective tissue disease, and liver function 
disorders.    
Modified Rodnan Skin Score (mRSS) evaluation
mRSS were evaluated by a trained rheumatologist 
consultant. Skin thickening was assessed by 
palpation of 17 areas of body skin (fingers, hands, 
forearms, arms, feet, legs, thighs, face, chest, 
and abdomen) using scale of 0 (Zero) to 3. “0” 
for normal skin; “1” for mild thickness; “2” for 
moderate thickness; and “3” for severe thickness.
B-cell Activating Factor (BAFF) test
Serum BAFF levels were measured using ELISA 
ABSTRACT
Background: Progression and expansion of skin fibrosis 
are the most important characteristics in determining 
clinical responses and prognosis of Systemic Sclerosis 
(SSc). Using modified Rodnan skin score (mRSS) can 
not rapidly detect a slight changes of  skin fibrosis in 
SSc patients. Biomarker assessment is needed to make 
a more objective, quantitative and rapid evaluation of 
the changes. Suggested potential useful biomarker is 
B-cell Activating Factor (BAFF), a positive regulator of B 
cell survival and maturation process. This study aimed 
to evaluate correlation between skin fibrosis based on 
mRSS and BAFF serum in SSc patients.
Methods: We used cross sectional methods. Enrolled 
all patients who met ACR EULAR 2013 criteria for 
SSc in Rheumatology Clinic Hasan Sadikin Hospital, 
Bandung, from November 2015 to March 2016. Subjects 
underwent medical record review, physical examination, 
mRSS measurement by rheumathologist, and blood 
tests. Data were analized using Rank-Spearman 
Correlation.
Results: Thirty seven subjects, with mean age 40+10 
years old. Subjects consisted of 23(62.2%) limited SSc 
and 14(37.8%) diffuse SSc. Mean BAFF serum was 
1160.2+424.7 pg/mL, no statistical difference were 
found between limited and diffuse type (p=0.662). 
Median mRSS results was 16 ranged from 2 to 36. 
Correlation between mRSS and BAFF serum was not 
significant (r=0.077; p=0.326).  
Conclusion: There is no correlation between mRSS 
and BAFF serum in systemic sclerosis at Hasan Sadikin 
Hospital.
Keywords: mRSS, BAFF, Systemic Sclerosis
Introduction
Systemic sclerosis is a chronic, progressive 
autoimmune disease affecting multiple organs 
with unknown etiology. Systemic sclerosis affects 
patients’ quality of life, psychology, physic, and 
economy.1 The expansion and progression of tissue 
fibrosis is an important clinical response to predict 
prognosis of systemic sclerosis disease.2 The 
Modified Rodnan Skin Score (mRSS) is the gold 
standard for evaluating skin fibrosis in systemic 
sclerosis patients.2,3 Implementation of mRSS 
in daily practice is still a problem as it requires 
experience and repetitive teaching processes.4 An 
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sandwich technique. Blood serum were drawn on the same 
day of mRSS evaluation. 
Other Data
Other data were taken from patient’s medical records, 
included: duration of illness; systemic sclerosis subtype; 
history of medication; and clinical manifestation based on 
ACR EULAR 2013. Additional laboratory analysis conducted 
were complete blood counts, serum glutamic oxaloacetic 
transaminase (SGOT), serum glutamic pyruvic transaminase 
(SGPT), creatinine, and urinalysis.
Statistical analysis
Data normality was tested using the Shapiro-Wilk test, 




There were 37 subjects recruited in this study, with an 
average age of 40 ± 10 years. The youngest patient was 16 
years old and the oldest were 62 years old. Subjects were 
divided into groups based on SSc type – 14 subjects (37.8%) 
had diffuse systemic sclerosis and 23 subjects (62.2%) had 
limited systemic sclerosis.  Four subjects (10.8%) included 
were diagnosed with systemic sclerosis for the first time, and 
had never received DMARD. The median of illness duration 
was 36 months with ranged from 3 months to 17 years. Basic 
characteristics of the subjects were served in Table 1.
Table 1. Basic Characteristics
Characteristics (units) Results




Systemic sclerosis type, N (%)
Limited 23 (62.2)
Diffuse 14 (37.8)
Patient Type, N (%)
Old 33 (89.2)
New 4 (10.8)
Illness Duration 36 (3 - 204) months**







ACR EULAR 2013 Clinical Manifestation , N (%)
Finger Fibrosis 37 (100)
Finger Edema 14 (37.8)
Finger Skar 28 (75.7)
Telangectasia
Salt and Pepper Appearance
12 (32.4)
20 (54.0)
Raynaud’s Phenomenon 29 (78.4)
MRSS 16 (2 - 36)**
*: average ± standard deviation (normal distribution data); **: median 
(min-max), for not normal distribution data.
The average serum BAFF found in this research was 1160.2 ± 
424.7 pg/mL. The average serum BAFF level in the limited-
type systemic sclerosis group was 1132.8 ± 470.5 pg/mL, 
while in the diffuse-type systemic sclerosis group was 1205.2 
± 348.5 pg/mL. There was no significant difference in the 
serum BAFF levels between two groups, as shown in table 3. 
The median mRSS among the subjects was 16, the lowest level 
was 2 and the highest 36. There was a significant difference in 
the mRSS levels of patients with diffuse and limited-type of 
systemic sclerosis, with p < 0.001, as shown in table 3.
Table 2. Laboratory Result
Characteristics (units) Results
Laboratory
Hb (g/dL) 13.2 ± 1.2*
Leucocyte (/mm3) 9932 ± 3176*
Thrombocytes (/mm3) 314.703 ± 86.570*
LED (mm/jam) 28 (1 - 87)**
SGOT (U/L) 17 (11 - 59)**
SGPT (U/L) 13 (5 - 42)**
Creatinine (mg/dL) 0.67 (0.44 - 1.92)**
Proteinuria (n (%))
Neg 31 (83.8 %)
1+ 6 (16.2 %)
   BAFF (pg/mL) 1160.2 ± 424.7*
*: average ± standard deviation (normal distribution data); **: median 
(min-max), for not normal distribution data.
Table 3. Analysis of the BAFF and mRSS difference between the 















Note: T-test analysis, significant if p-value<0.05
*: average ± standard deviation (normal distribution data); **: median 
(min-max), for not normal distribution data.
Bivariate analysis of the severity of skin fibrosis based on 
the mRSS and serum BAFF levels showed no significant 
correlation between mRSS and serum BAFF levels (r = 
-0.077, p = 0.326), as shown in table 4. Bivariate analysis 
on the newly diagnosed patients, or those who have never 
received DMARDs, showed that there is a positive correlation 
between mRSS and the serum BAFF levels, though there was 
no significant statistical difference (r = 0.400, p = 0.300), as 
shown in table 5. Analysis subjects based on history of using 
steroid also showed no significant correlation between mRSS 
and the BAFF levels in patients who have used and have never 
used steroids, as shown in table 5. 
Table 4. mRSS and BAFF Serum Bivariate Analysis
Variable  mRSS 
R p-value
BAFF (pg/dL) -0.077 0.326*
Note: Rank Spearman correlation analysis, *significant if p<0.05
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Figure 1. mRSS and Serum BAFF Distribution Diagram 





                      
Receiving DMARD  (n=33)
Not receiving DMARD  (n=4)
Receiving Steroid (n=29)









Note: Rank Spearman Correlation Analysis, significant if p-value<0,05
Discussion
Average age of the subjects was 40 ± 10 years. It is consistent 
with the literature which stated most systemic sclerosis occur 
in the third and fourth decades of life.16,17 The average age of 
our subjects do not differ greatly from the previous research 
conducted by Fawzy, et al, which reported average age of 
43.75 ± 14 years14, and Abdo, et al research, which reported 
average age of 38.2 ± 12.1 years.15 Subjects were dominated 
by women, account for 97.3% of all subjects. This is 
consistent with the fact that systemic sclerosis mostly occurs 
in women.16,18
We found Raynaud’s phenomenon in 29 subjects (78.4%). 
Raynaud’s phenomenon is the most common complaint at the 
beginning of the illness.18,19 Research conducted by Abdo, et 
al showed only 13 (21.7%) subjects suffered from Raynaud’s 
phenomenon, whereas Fawzy, et al found that all subjects 
(12 patients) with Raynaud’s phenomenon.14,15 Differences 
of this clinical manifestations may be attributed with the 
management and the onset of the disease. The high percentage 
of Raynaud’s phenomenon as reported by Fawzy, et al may 
be occurred because all recruited subjects had not received 
DMARD or corticosteroid therapy. While, in our research 
as well as in Abdo, et al study, major subjects had received 
DMARDs and other symptomatic therapy rountinely.
The average BAFF level in this research was 1160.2 ± 
424.7 pg/mL. Fawzy reported a similar BAFF level of 1060 ± 
290 pg/mL, whereas Abdo, et al also reported a relative similar 
BAFF level of 1100 ± 835.4 pg/mL14,15 In this research, we 
found no significant difference in the BAFF levels of patients 
with diffuse and limited systemic sclerosis (p = 0.622), as 
shown in table 4. A similar result was reported by Abdo, et al 
(p = 0.370),15 but it is not concordance with the result reported 
by Matsushita, et al and Fawzy, et al.
Various factors may influence the results of the correlation 
between BAFF level and MRSS result. We suggested the 
difference result between our research and Abdo, et al study, 
compared to the research by Matsushita, et al and Fawzy, 
et al were happened due to the medication received by the 
subjects. In this research, 89.2%  subjects had already received 
methotrexate. Only 4 patients who were newly diagnosed with 
systemic sclerosis had never received methotrexate. Steroids 
had also been given to 29 subjects (78.4%), and two subjects 
(5.4%) were undergoing cyclophosphamide chemotherapy. 
The medication characteristics in this study was quite 
similar to the research conducted by Abdo, et al where 65% 
patients were receiving methotrexate and oral corticosteroids, 
and 21.7% patients were undergoing cyclophosphamide 
chemotherapy.15
This subjects’ medication characteristic was differed 
greatly from the study conducted by Matsushita, et al. 
which from the 83 patients enrolled, only 5 were receiving 
low dose corticosteroids, and 8 were receiving low dose 
D-penicillamine, while the others were not received any 
other immunosuppressive therapy.10 Likewise the medication 
characteristic in research conducted by Fawzy, et al, All 
subjects were a newly diagnosed SSc patients, so they had 
never received corticosteroids or DMARD therapy before the 
study began.14
Methotrexate is a conventional DMARD. It is an anti-
metabolite drug which inhibits the dihydrofolate reductase 
enzyme and causes a disturbance in the formation of DNA 
and nucleotides.20 Low dose methotrexate can be used to 
treat inflammatory of an autoimmune disease.  The effects 
of methotrexate on the immune system include decreasing 
proinflammatory cytokines, releasing extracellular adenosine, 
and inhibiting activation of T-cell.20
Methotrexate is the choosen therapy for early phase skin 
fibrosis in diffuse systemic sclerosis.20,21 The efficacy of 
methotrexate towards skin fibrosis has been studied in two 
randomized controlled trials but no significant difference 
were reported in those trials. Van den Hoogen, et al study, 
reported higher mRSS improvement after receiving 15 mg 
intramuscular methotrexate for 24 weeks in comparison 
to placebo (p = 0.06).22 Pope, et al study, also reported 
an improvement of mRSS after 12 months methotrexate 
treatment, though no significant difference were found as the 
number of subjects were too small.23
Methotrexate can influence the number and the activity of 
B and T cells, and possibly the level of BAFF in the blood. 
Therefore, we suggested that subjects who have received 
DMARDs, specifically methotrexate, will not showing any 
correlation between mRSS and serum BAFF level. This is 
supported by individual analysis of the correlation between 
mRSS and BAFF in 4 naïve subjects included in our study, 
where a moderate correlation was identified (r=0.400; 
p=0.300), though not statistically significant  was found as the 
sample size is relatively small. Therefore, the use of DMARD 
is yet to be determined as a factor that influences the level of 
BAFF. 
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Other suggestion of medication that can influence the 
insignificant corellation result is the use of corticosteroid. 
Corticosteroids are the most common drug used for systemic 
sclerosis24, although it has never undergone any trials regarding 
its efficacy and safety. Even, at high dose, corticosteroid was 
reported have corellation with the occurance of renal crisis.24 
The use of steroids in autoimmune diseases can causing 
transient lymphocytopenia by changing the way lymphocytes 
re-circulate, and also inducing lymphocyte death. The primary 
immune suppression effects of steroids is the inhibition of 
cytokines and T cell activation.20 With those direct effects on 
lymphocytes, the use of corticosteroids may have an effect 
on the serum BAFF level too. However, researches regarding 
the effect of corticosteroids on BAFF levels have never been 
done, and the presence of a direct effect of steroids on BAFF 
is still unknown. In this study, we also analyzed the correlation 
between mRSS and the BAFF level in patients using and not 
using steroids, and no significant correlation was found with 
either groups (Table 5).
We realize some limitations on this study that may affect 
the study results. Most subjects have received DMARD 
therapy, that can affect the number of B cells and T cells, 
and we suggested might also affect the level of BAFF in the 
serum. Besides, duration and DMARD dose may also affect 
our observation result. However, we only recorded the type of 
DMARD drugs, but not recorded the duration of treatment and 
dosage of the drug. 
Conclusion
In conclusion, we found no significant correlation between 
mRSS and the level of BAFF in SSc patients. The BAFF 
level might be affected by medication received by the 
patients, especially methotrexate. Patients undergo DMARD 
therapy showed no correlation between mRSS and BAFF, 
whereas naïve patients might have a moderate correlation 
between mRSS and BAFF. To provide better understanding 
of pathogenesis and relationship beetween mRSS and BAFF, 
there should be a larger-scale studies addressing naive subject, 
with cohort or case control design studies.  
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